Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Down 97.1% in March

Bioxytran, Inc. (OTCMKTS:BIXT) saw a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 300 shares, a decrease of 97.1% from the February 26th total of 10,300 shares. Based on an average daily volume of 1,769,827 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are sold short. Approximately 0.0% of the company’s shares are sold short. Based on an average daily volume of 1,769,827 shares, the days-to-cover ratio is currently 0.0 days.

Bioxytran Stock Performance

OTCMKTS BIXT traded up $0.01 during trading on Tuesday, hitting $0.05. The stock had a trading volume of 210,476 shares, compared to its average volume of 405,921. Bioxytran has a one year low of $0.03 and a one year high of $0.23. The stock has a 50 day simple moving average of $0.05 and a 200 day simple moving average of $0.06. The stock has a market capitalization of $5.51 million, a price-to-earnings ratio of -1.62 and a beta of 2.14.

Bioxytran Company Profile

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.